Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,104.52% | -45.64% | -126.26% | 132.63% | -7.88% |
| Total Depreciation and Amortization | 4.74% | 11.64% | 5.85% | 18.75% | 13.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8,624.90% | -77.33% | 2,957.14% | -108.20% | -42.63% |
| Change in Net Operating Assets | 140.71% | 383.13% | 159.61% | 42.46% | 23.98% |
| Cash from Operations | 80.57% | -8.41% | -62.96% | 2,229.31% | 3.86% |
| Capital Expenditure | 70.54% | 77.59% | -2.03% | -- | 9.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 70.54% | 77.59% | -2.03% | -- | 9.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 33.33% | 40.00% | 50.00% | -150.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 60.87% | -- | -- | -- | -43.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | 93.56% |
| Cash from Financing | 40.36% | 40.00% | 49.35% | -150.00% | 32.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 265.95% | 879.79% | 12.48% | 61.37% | 57.50% |